Alfa-carboline inhibitors of NPM-ALK, RET, and Bcr-Abl
AssigneesUniversita Degli Studi Di Milano-Bicocca, Universite De Geneve, Universite Claude Bernard De Lyon 1
InventorsCarlo Gambacorti Passerini, Luca Mologni, Leonardo Scapozza, Shaheen Ahmed, Peter G. Goekjian, David Gueyrard, Florence Popowycz, Benoit Joseph, Cedric Schneider, Pierre Garcia
Life of this patent
Estimating the term…
Abstract
The present invention relates to compounds of formula (I) wherein R1, R2 and R3 are as defined in the description, to their pharmaceutical compositions and use thereof for the treatment of cancer expressing oncogenic ALK protein, particularly anaplastic large cell lymphoma (ALCL), diffuse large B cell lymphoma (DLBCL), inflammatory myofibroblastic tumors (IMT) and non-small cell lung cancer (NSCLC).
Claims11
A compound of formula (I):
- wherein
- when R1 is nil or when R1 is attached in the 2 position of the α-carboline ring, R1 is selected from the group consisting of:
- when R1 is attached in the 3 position of the α-carboline ring, R1 is selected from the group consisting of:
- when R1 is attached in the 4 position of the α-carboline ring, R1 is selected from the group consisting of:
- wherein R2 is selected from the group consisting of:
- wherein R3 is selected from the group consisting of hydrogen, methyl, ethoxymethyl, tert-butyloxycarbonyl and benzenesulfonyl;
- wherein a dashed line across a bond indicates the point of attachment of the group to the α-carboline ring,
- or a stereoisomer, enantiomer, diastereoisomer or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.